Drug intelligence / Profile preview

AIP 308

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP 308 is a therapeutic radiopharmaceutical candidate being developed by Advanced Innovative Partners (AIP) for the treatment of Glioblastoma Multiforme (GBM). As a targeted radionuclide therapy, it is designed to deliver ionizing radiation directly to malignant glioma cells, aiming to induce DNA damage and cell death while sparing surrounding healthy brain tissue. The program is currently in the preclinical stage of development and serves as the therapeutic counterpart to AIP 307, which is being developed as a diagnostic imaging agent for the same indication.

Other names: AIP-308AIP308AIP 308

Beyond the preview

Go deeper on AIP 308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP 308.

Explore the full profile